NCR Online Journal

The Surgical Site Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Surgical Site Infections Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Surgical Site Infections Market.

Some of the key takeaways from the Surgical Site Infections Pipeline Report: 

• Companies across the globe are diligently working toward developing novel Surgical Site Infections treatment therapies with a considerable amount of success over the years. 

• Surgical Site Infections companies working in the treatment market are MinaPharm Pharma, Duke Clinical Research, Zurex Pharma, Inc., Merck Sharp & Dohme LLC, Destiny Pharma Plc, PolyPid Ltd., Durata Therapeutics, Lindenhofgruppe AG, Veristat, Inc, and others, are developing therapies for the Surgical Site Infections treatment 

• Emerging Surgical Site Infections therapies in the different phases of clinical trials are- Ciprodiazole, DFA-02, ZuraPrep, Ertapenem, XF-73, D-PLEX, Dalbavancin, BACTROBAN® Nasal ong, E-101, and others are expected to have a significant impact on the Surgical Site Infections market in the coming years.   

• In January 2023, PolyPid Ltd. provided a positive regulatory update for D-PLEX100 for the prevention of abdominal colorectalsurgical site infections (SSIs). Following a recent type D meeting communication with the US Food and Drug Administration (FDA)on the SHIELD I Phase III data, the Company now has clarity regarding the regulatory pathway toward a potential New DrugApplication (NDA) submission.

• In April 2023, The inaugural randomized clinical trial associated with registry data from the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) indicates that modifying antibiotics prior to pancreatoduodenectomy, commonly referred to as the Whipple procedure, leads to a decrease in the occurrence of surgical site infections (SSIs) among patients undergoing the surgery.

• In April 2022, Mölnlycke expanded in Malaysia by constructing a new surgical glove factory. The company is increasing its manufacturing capacity to ensure that it can continue to satisfy the growing demand for Biogel gloves.

Surgical Site Infections Overview

Surgical Site Infections (SSIs) are infections that occur at the site of a surgical incision or in the surrounding tissue following a surgical procedure. These infections can range from superficial infections involving the skin and subcutaneous tissue to more severe infections affecting deeper layers of tissue, such as muscles and organs.

Get a Free Sample PDF Report to know more about Surgical Site Infections Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/surgical-site-infections-ssi-pipeline-insight

Emerging Surgical Site Infections Drugs Under Different Phases of Clinical Development Include:

• Ciprodiazole: MinaPharm Pharma

• DFA-02: Duke Clinical Research

• ZuraPrep: Zurex Pharma, Inc.

• Ertapenem: Merck Sharp & Dohme LLC

• XF-73: Destiny Pharma Plc

• D-PLEX: PolyPid Ltd.

• Dalbavancin: Durata Therapeutics

• BACTROBAN® Nasal ong: Lindenhofgruppe AG

• E-101: Veristat, Inc

Surgical Site Infections Route of Administration

Surgical Site Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Inhalation

• Inhalation/Intravenous/Oral

• Intranasal

• Intravenous

• Intravenous/ Subcutaneous

• NA

• Oral

• Oral/intranasal/subcutaneous

• Parenteral

• Subcutaneous

Surgical Site Infections Molecule Type

Surgical Site Infections Products have been categorized under various Molecule types, such as

• Antibody

• Antisense oligonucleotides

• Immunotherapy

• Monoclonal antibody

• Peptides

• Protein

• Recombinant protein

• Small molecule

• Stem Cell

• Vaccine

Surgical Site Infections Pipeline Therapeutics Assessment

• Surgical Site Infections Assessment by Product Type

• Surgical Site Infections By Stage and Product Type

• Surgical Site Infections Assessment by Route of Administration

• Surgical Site Infections By Stage and Route of Administration

• Surgical Site Infections Assessment by Molecule Type

• Surgical Site Infections by Stage and Molecule Type

DelveInsight’s Surgical Site Infections Report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Surgical Site Infections product details are provided in the report. Download the Surgical Site Infections pipeline report to learn more about the emerging Surgical Site Infections therapies

Some of the key companies in the Surgical Site Infections Therapeutics Market include:

Key companies developing therapies for Surgical Site Infections are – Becton, Dickinson and Company, 3M Company, Biomerieux SA, Getinge Group, and Johnson & Johnson, and others.

Surgical Site Infections Pipeline Analysis:

The Surgical Site Infections pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Surgical Site Infections with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Surgical Site Infections Treatment.

• Surgical Site Infections key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Surgical Site Infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Surgical Site Infections market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Surgical Site Infections drugs and therapies

Surgical Site Infections Pipeline Market Drivers

• Rising number of surgeries and the growing geriatric population, increasing concern about hospital acquired infections along with rising incidences of hospital-acquired infections are some of the important factors that are fueling the Surgical Site Infections Market.

Surgical Site Infections Pipeline Market Barriers

• However, lack of awareness regarding infection control measures, difficulty in identifying the site of infection and other factors are creating obstacles in the Surgical Site Infections Market growth.

Scope of Surgical Site Infections Pipeline Drug Insight    

• Coverage: Global

• Key Surgical Site Infections Companies: MinaPharm Pharma, Duke Clinical Research, Zurex Pharma, Inc., Merck Sharp & Dohme LLC, Destiny Pharma Plc, PolyPid Ltd., Durata Therapeutics, Lindenhofgruppe AG, Veristat, Inc, and others

• Key Surgical Site Infections Therapies: Ciprodiazole, DFA-02, ZuraPrep, Ertapenem, XF-73, D-PLEX, Dalbavancin, BACTROBAN® Nasal ong, E-101, and others

• Surgical Site Infections Therapeutic Assessment: Surgical Site Infections current marketed and Surgical Site Infections emerging therapies

• Surgical Site Infections Market Dynamics: Surgical Site Infections market drivers and Surgical Site Infections market barriers 

Request for Sample PDF Report for Surgical Site Infections Pipeline Assessment and clinical trials

Table of Contents

1. Surgical Site Infections Report Introduction

2. Surgical Site Infections Executive Summary

3. Surgical Site Infections Overview

4. Surgical Site Infections- Analytical Perspective In-depth Commercial Assessment

5. Surgical Site Infections Pipeline Therapeutics

6. Surgical Site Infections Late Stage Products (Phase II/III)

7. Surgical Site Infections Mid Stage Products (Phase II)

8. Surgical Site Infections Early Stage Products (Phase I)

9. Surgical Site Infections Preclinical Stage Products

10. Surgical Site Infections Therapeutics Assessment

11. Surgical Site Infections Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Surgical Site Infections Key Companies

14. Surgical Site Infections Key Products

15. Surgical Site Infections Unmet Needs

16 . Surgical Site Infections Market Drivers and Barriers

17. Surgical Site Infections Future Perspectives and Conclusion

18. Surgical Site Infections Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/